Boston Scientific Corporation
Boston Scientific Corporation’s EV / EBITDA at a glance
Boston Scientific Corporation reports ev / ebitda of 36.1x for Dec 2024. The prior period recorded 26.8x (Dec 2023). Year over year the metric moved +9.28 (+34.6%). The rolling three-period average stands at 30x. Data last refreshed Dec 18, 2025, 7:58 AM.
Latest reading
36.1x · Dec 2024
YoY movement
+9.28 (+34.6%)
Rolling average
30x
Current EV / EBITDA
36.1x
+9.28
+34.6%
Rolling average
30x
Latest Value
36.1x
Dec 2024
YoY Change
+9.28
Absolute
YoY Change %
+34.6%
Rate of change
3-Period Avg
30x
Smoothed
Narrative signal
Boston Scientific Corporation’s ev / ebitda stands at 36.1x for Dec 2024. Year-over-year, the metric shifted by +9.28, translating into a +34.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How ev / ebitda shapes Boston Scientific Corporation's story
As of Dec 2024, Boston Scientific Corporation reports ev / ebitda of 36.1x. Use EV/EBITDA to benchmark acquisition multiples, leverage-adjusted valuation, and comparable transaction ranges.
Why EV/EBITDA matters
It normalizes valuation across different leverage levels, making it a go-to metric for M&A and cross-company comparisons.
Watch for cyclical swings
EBITDA can swing with cycle-sensitive businesses. Track multi-year averages and peak vs. trough to understand value ranges.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
61.3%
Operating Margin
15.7%
Net Profit Margin
11.1%
Return on Equity
8.5%
Return on Assets
4.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Boston Scientific Corporation (BSX) FAQs
Answers tailored to Boston Scientific Corporation’s ev / ebitda profile using the latest Financial Modeling Prep data.
What is Boston Scientific Corporation's current ev / ebitda?
As of Dec 2024, Boston Scientific Corporation reports ev / ebitda of 36.1x. This reading reflects the latest filings and price data for BSX.
How is Boston Scientific Corporation's ev / ebitda trending year over year?
Year-over-year, the figure shifts by +9.28 (+34.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for BSX.
Why does ev / ebitda matter for Boston Scientific Corporation?
The enterprise value to EBITDA ratio evaluates valuation relative to operating cash flow before capital structure impacts. For Boston Scientific Corporation, operating within Healthcare — Medical - Devices, tracking this metric helps benchmark management's execution against close competitors.
Is Boston Scientific Corporation's ev / ebitda above its recent average?
Boston Scientific Corporation's rolling three-period average sits at 30x. Comparing the latest reading of 36.1x to that baseline highlights whether momentum is building or fading for BSX.
How frequently is Boston Scientific Corporation's ev / ebitda refreshed?
Data for BSX was last refreshed on Dec 18, 2025, 7:58 AM and updates automatically every 24 hours, keeping your valuation inputs current.